| 1 |
Takada T. Progress in progressive pulmonary fibrosis: biomarkers of systemic sclerosis-associated interstitial lung disease[J]. Rheumatology (Oxford), 2024, 63 (11): 2907-2908.
|
| 2 |
D'Agnano V, Mariniello DF, Ruotolo M, et al. Targeting progression in pulmonary fibrosis: an overview of underlying mechanisms, molecular biomarkers, and therapeutic intervention[J]. Life (Basel), 2024, 14 (2): 229.
|
| 3 |
Shi N, Wang Z, Zhu H, et al. Research progress on drugs targeting the TGF-β signaling pathway in fibrotic diseases[J]. Immunol Res, 2022, 70 (3): 276-288.
|
| 4 |
Deng X, Jin K, Li Y, et al. Platelet-derived growth factor and transforming growth factor β1 regulate ARDS-associated lung fibrosis through distinct signaling pathways[J]. Cell Physiol Biochem, 2015, 36 (3): 937-946.
|
| 5 |
Huh JY, Lee JH, Song JW. Efficacy and safety of combination therapy with pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis[J]. Front Pharmacol, 2023, 14: 1301923.
|
| 6 |
Budin CE, Cocuz IG, Sabau AH, et al. Pulmonary fibrosis related to amiodarone—is it a standard pathophysiological pattern? A case-based literature review[J]. Diagnostics (Basel), 2022, 12 (12): 3217.
|
| 7 |
Peng M, Yan QH, Gao Y, et al. Correlation between circulating endothelial cell level and acute respiratory distress syndrome in postoperative patients[J]. World J Clin Cases, 2021, 9 (32): 9731-9740.
|
| 8 |
Koudstaal T, Funke-Chambour M, Kreuter M, et al. Pulmonary fibrosis: from pathogenesis to clinical decision-making[J]. Trends Mol Med, 2023, 29 (12): 1076-1087.
|
| 9 |
Alzahrani B, Gaballa MMS, Tantawy AA, et al. Blocking Toll-like receptor 9 attenuates bleomycin-induced pulmonary injury[J]. J Pathol Transl Med, 2022, 56 (2): 81-91.
|
| 10 |
Enomoto N. Pathological roles of pulmonary cells in acute lung injury: lessons from clinical practice[J]. Int J Mol Sci, 2022, 23 (23): 15027.
|
| 11 |
张丽敏，张志明，李兴芳，等.巨噬细胞程序性死亡在急性肺损伤/急性呼吸窘迫综合征中的研究进展[J/OL].中华危重症医学杂志（电子版），2024，17（2）：148-154.
|
| 12 |
Li HH, Wang CW, Chang CH, et al. Relationship between mechanical ventilation and histological fibrosis in patients with acute respiratory distress syndrome undergoing open lung biopsy[J]. J Pers Med, 2022, 12(3): 474.
|
| 13 |
李振翮，魏长青，甄国栋，等.脓毒症并发急性呼吸窘迫综合征患者血清S1P、Wnt5a变化及其临床意义[J/OL].中华危重症医学杂志（电子版），2024，17（4）：293-300.
|
| 14 |
Ambardar SR, Hightower SL, Huprikar NA, et al. Post-COVID-19 pulmonary fibrosis: novel sequelae of the current pandemic[J]. J Clin Med, 2021, 10 (11): 2542.
|
| 15 |
Mostafa M, Adolf Helmy M, Magdy Milad L, et al. Patient self-induced lung injury risk in severe COVID-19[J]. Anaesth Crit Care Pain Med, 2022, 41 (2): 101018.
|
| 16 |
Makena P, Kikalova T, Prasad GL, et al. Oxidative stress and lung fibrosis: towards an adverse outcome pathway[J]. Int J Mol Sci, 2023, 24 (15): 12490.
|
| 17 |
Detsika MG, Palamaris K, Dimopoulou I, et al. The complement cascade in lung injury and disease[J]. Respir Res, 2024, 25 (1): 20.
|
| 18 |
Cerier EJ, Bharat A. Lung transplantation for coronavirus disease 2019 acute respiratory distress syndrome/fibrosis: silver lining of a global pandemic[J]. Curr Opin Organ Transplant, 2023, 28 (3): 157-162.
|
| 19 |
Agarwal AK, Huda N. Interstitial pulmonary fibrosis[M]. Treasure Island (FL): StatPearls Publishing, 2024.
|
| 20 |
Read J, Reid AT, Thomson C, et al. Alveolar epithelial cells of lung fibrosis patients are susceptible to severe virus-induced injury[J]. Clin Sci (Lond), 2024, 138 (8): 537-554.
|
| 21 |
Bahram Yazdroudi F, Malek A. Optimal controlling of anti-TGF-β and anti-PDGF medicines for preventing pulmonary fibrosis[J]. Sci Rep, 2023, 13 (1): 15073.
|
| 22 |
Song L, Li K, Chen H, et al. Cell cross-talk in alveolar microenvironment: from lung injury to fibrosis[J]. Am J Respir Cell Mol Biol, 2024, 71 (1): 30-42.
|
| 23 |
井方雪，董昭兴.巨噬细胞极化在肺纤维化中作用的研究进展[J].浙江医学，2025，47（18）：2004-2008.
|
| 24 |
Wang X, Zhou J, Li X, et al. The role of macrophages in lung fibrosis and the signaling pathway[J]. Cell Biochem Biophys, 2024, 82 (2): 479-488.
|
| 25 |
Cao W, Zeng Y, Su Y, et al. The involvement of oxidative stress and the TLR4/NF-κB/NLRP3 pathway in acute lung injury induced by high-altitude hypoxia[J]. Immunobiology, 2024, 229 (3): 152809.
|
| 26 |
Kasuya Y, Kim JD, Hatano M, et al. Pathophysiological roles of stress-activated protein kinases in pulmonary fibrosis[J]. Int J Mol Sci, 2021, 22 (11): 6041.
|
| 27 |
Ye C, Xu B, Yang J, et al. Mucin1 relieves acute lung injury by inhibiting inflammation and oxidative stress[J]. Eur J Histochem, 2021, 65 (4): 3331.
|
| 28 |
Su PC, Chen CY, Yu MH, et al. Fully human chitinase-3 like-1 monoclonal antibody inhibits tumor growth, fibrosis, angiogenesis, and immune cell remodeling in lung, pancreatic, and colorectal cancers[J]. Biomed Pharmacother, 2024, 176: 116825.
|
| 29 |
Flieβer E, Jandl K, Lins T, et al. Lung fibrosis is linked to increased endothelial cell activation and dysfunctional vascular barrier integrity[J]. Am J Respir Cell Mol Biol, 2024 71 (3): 318-331.
|
| 30 |
Yanagihara T, Tsubouchi K, Zhou Q, et al. Vascular-parenchymal cross-talk promotes lung fibrosis through BMPR2 signaling[J]. Am J Respir Crit Care Med, 2023, 207 (11): 1498-1514.
|
| 31 |
Bahram Yazdroudi F, Malek A. Optimal control of TGF-β to prevent formation of pulmonary fibrosis[J]. PLoS One, 2022, 17 (12): e0279449.
|
| 32 |
Klinkhammer BM, Floege J, Boor P. PDGF in organ fibrosis[J]. Mol Aspects Med, 2018, 62: 44-62.
|
| 33 |
Liu QH, Zhang K, Feng SS, et al. Rosavin alleviates LPS-induced acute lung injure by modulating the TLR-4/NF-κB/MAPK singnaling pathways[J]. Int J Mol Sci, 2024, 25 (3): 1875.
|
| 34 |
Miao Y, Wang Y, Bi Z, et al. Antifibrotic mechanism of avitinib in bleomycin-induced pulmonary fibrosis in mice[J]. BMC Pulm Med, 2023, 23 (1): 94.
|
| 35 |
Amati F, Stainer A, Polelli V, et al. Efficacy of pirfenidone and nintedanib in interstitial lung diseases other than idiopathic pulmonary fibrosis: a systematic review[J]. Int J Mol Sci, 2023, 24 (9): 7849.
|
| 36 |
Zhao Y, Yan Z, Liu Y, et al. Effectivity of mesenchymal stem cells for bleomycin-induced pulmonary fibrosis: a systematic review and implication for clinical application[J]. Stem Cell Res Ther, 2021, 12 (1): 470.
|
| 37 |
Li JP, Wu KH, Chao WR, et al. Immunomodulation of mesenchymal stem cells in acute lung injury: from preclinical animal models to treatment of severe COVID-19[J]. Int J Mol Sci, 2022, 23 (15): 8196.
|
| 38 |
Diesler R, Cottin V. Pulmonary fibrosis associated with rheumatoid arthritis: from pathophysiology to treatment strategies[J]. Expert Rev Respir Med, 2022, 16 (5): 541-553.
|
| 39 |
Tanner L, Single AB, Bhongir RKV, et al. Small-molecule-mediated OGG1 inhibition attenuates pulmonary inflammation and lung fibrosis in a murine lung fibrosis model[J]. Nat Commun, 2023, 14 (1): 643.
|
| 40 |
Yue L, Chen F, Liu X, et al. miR-23b-3p ameliorates LPS-induced pulmonary fibrosis by inhibiting EndMT via DPP4 inhibition[J]. Mol Biotechnol, 2025, 67 (1): 175-186.
|